TD Cowen lowered the firm’s price target on Tandem Diabetes (TNDM) to $20 from $27 and keeps a Buy rating on the shares. The firm notes that as part of its Q2 report, Tandem reduced its 2025 U.S. sales guidance to $700M from $725M-$730M, citing its commercial transformation as well as increased U.S. competition, which the company feels is likely to cause “pausing” in the second half of 2025. While TD Cowen continues to like Tandem’s portfolio and pipeline, especially longer term, it expects concerns about U.S. competition to loom over the stock in the second half of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target lowered to $24 from $59 at Canaccord
- Tandem Diabetes announces medical device correction for t:slim X2 insulin pumps
- Tandem Diabetes downgraded to Hold from Buy at Nephron Research
- Tandem Diabetes price target lowered to $13 from $20 at Wells Fargo
- Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler